{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:09Z","timestamp":1786120269713,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/mcg.0b013e318231faae","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T04:23:18Z","timestamp":1318998198000},"page":"168-171","source":"Crossref","is-referenced-by-count":21,"title":["Durability of Rifaximin Response in Hepatic Encephalopathy"],"prefix":"10.1097","volume":"46","author":[{"given":"Guy W.","family":"Neff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Broda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinuthala","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyingi","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-2008-1040322","article-title":"Hepatic encephalopathy.","volume":"28","author":"Cordoba","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R2-14-20210305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM199708143370707","article-title":"Treatment of hepatic encephalopathy.","volume":"337","author":"Riordan","year":"1997","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R3-14-20210305","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000089784","article-title":"Management of hepatic encephalopathy: focus on antibiotic therapy.","volume":"73","author":"Festi","year":"2006","journal-title":"Digestion"},{"key":"R4-14-20210305","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gut.2007.122176","article-title":"Pathogenetic mechanisms of hepatic encephalopathy.","volume":"57","author":"Haussinger","year":"2008","journal-title":"Gut"},{"key":"R5-14-20210305","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy.","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"R6-14-20210305","first-page":"17","article-title":"Review article: bacterial flora and pathogenesis in hepatic encephalopathy.","volume":"25","author":"Williams","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-14-20210305","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Hepatic encephalopathy.","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"suppl 2","key":"R8-14-20210305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-2007-984576","article-title":"An algorithm for the management of hepatic encephalopathy.","volume":"27","author":"Mullen","year":"2007","journal-title":"Semin Liver Dis"},{"issue":"suppl 1","key":"R9-14-20210305","first-page":"S3","article-title":"Role of antibiotics in the management of hepatic encephalopathy.","volume":"5","author":"Maddrey","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"R10-14-20210305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14787210.4.3.417","article-title":"Current and future developments in travelers diarrhea therapy.","volume":"4","author":"Koo","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"suppl 1","key":"R11-14-20210305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"R12-14-20210305","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2146\/ajhp070298","article-title":"Rifaximin for the treatment of hepatic encephalopathy.","volume":"65","author":"de Melo","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"R14-14-20210305","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R15-14-20210305","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.transproceed.2006.10.107","article-title":"Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.","volume":"38","author":"Neff","year":"2006","journal-title":"Transplant Proc"},{"key":"R16-14-20210305","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.","volume":"13","author":"Miglio","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"R17-14-20210305","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-14-20210305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lt.20824","article-title":"A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation.","volume":"12","author":"Cholongitas","year":"2006","journal-title":"Liver Transpl"},{"key":"R19-14-20210305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-230X-8-26","article-title":"Rifaximin for maintenance therapy in antibiotic-dependent pouchitis.","volume":"8","author":"Shen","year":"2008","journal-title":"BMC Gastroenterol"},{"key":"R20-14-20210305","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3748\/wjg.v13.i2.264","article-title":"Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease.","volume":"13","author":"Colecchia","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R21-14-20210305","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease.","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transpl"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004836-201202000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:46Z","timestamp":1786047886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-201202000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318231faae","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}